OncoMatch/Clinical Trials/NCT06547736
Exploratory Platform Research on Precision Therapy of Advanced Pancreatic Cancer
Is NCT06547736 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including SHR-A2102 or/and HRS-4642 and SHR-A1904 or/and HRS-4642 for pancreatic cancer.
Treatment: SHR-A2102 or/and HRS-4642 · SHR-A1904 or/and HRS-4642 · SHR-A1811 or/and HRS-4642 · SHR-A2102, HRS4642 and Adebrelimab — The study is being conducted to evaluate the safety, tolerability and efficacy of ADC drugs monotherapy or combination therapy with HRS-4642 or immunotherapy in subjects with locally advanced or metastatic pancreatic cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Pancreatic Cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: systemic antitumor therapy
Cannot have received: palliative radiotherapy
Lab requirements
Blood counts
Kidney function
Liver function
Adequate marrow and organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06547736 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior systemic antitumor therapy, palliative radiotherapy disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages